News
News
AAA Opens Lutathera Expanded Access Program In U.S. to Eligible Patients And Announces Forthcoming NDA Filing to FDA and EMA.
AAA today announced that the company has initiated an expanded access program (EAP) in the United States for the investigational product, Lutathera. Through the program, Lutathera is being made available for patients suffering from inoperable, somatostatin receptor positive, midgut carcinoid tumors, progressive under somatostatin analogue therapy. Healthcare professionals and patients can learn more about the Lutathera EAP by visiting www.clinicaltrials.gov (trial number: NCT02705313). To read more visit AAA's website.
New articles have been added to our file section.
Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths.
Vikas Prasad & Lisa Bodei & Mark Kidd & Irvin M. Modlin
90Y Radioembolization After Radiation Exposure from Peptide Receptor Radionuclide Therapy.90Y Radioembolization After Radiation Exposure from Peptide Receptor Radionuclide Therapy.
Samer Ezziddin, Carsten Meyer, Stanislawa Kahancova, Torjan Haslerud, Winfried Willinek, Kai Wilhelm, Hans-Jürgen Biersack, and Hojjat Ahmadzadehfar
More resource documents can be found in our file section.
For the second year in a row, NorCal CarciNET Community and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) held a patient education day during the SNMMI's Annual Meeting. The program took place on June 8th and began with three (3) general lectures about the definition of nuclear medicine and molecular imaging, safety of nuclear medicine, the value of patient and physician partnerships in care management. The afternoon concluded with breakout sessions focused on hot topics in colon cancer, prostate cancer, thyroid diseases, and neuroendocrine tumors. The total number of attendees was 120 with over 50 attending the NET breakout. To see the complete program and recordings of the breakout sessions, visitwww.snmmi.org/PED. The
Ga-68-labeled somatostatin analogs are important imaging agents to detect and manage neuroendocrine tumors (NETs). The SNMMI formed the 68Ga Users Group to advance the use of these imaging agents in the US. Members of the Users Group developed harmonized release criteria, an imaging manual, generic data collection forms and a draft informed consent form to aid the community in establishing investigator-sponsored trials. In October 2013, the Society of Nuclear Medicine and Molecular Imaging
BREAKING NEWS – the radiopharmaceutical Gallium-68 (DOTA0-hel-Tyr3) octreotide (Ga-68 DOTATOC) has been designated as an orphan drug by the US Food and Drug Administration (FDA) for the management of neuroendocrine tumors. This designation is significant because it may lead to faster approval of the agent, which would greatly benefit carcinoid/NET patients in the United States. Click here to read the full release the Society of Nuclear Medicine and Molecular Imaging and from
Photos from Warmth Manila
Click here to view on non flash device.
Click on the photo to see full screen and to download.
Our very dear friend and colleague, Prof. Dr. Ajit Kumar Padhy, passed away suddenly on the 22nd of August 2013 after suffering from a massive heart attack.
Prof Padhy was a Senior Consultant in the Singapore General Hospital, Department of Nuclear Medicine & PET since September 2005. Prior to that, he was the Head of Nuclear Medicine, IAEA, in the Division of Human Health from 1997 to 2004, and he was Faculty of Nuclear Medicine, AIIMS, New Delhi, India since the 1970’s.